Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus mycophenolate mofetil for class III/IV lupus nephritis
2016-003201-34Phase 3
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Rituximab + mycophenolate mofetil with Placebo + mycophenolate mofetil (2 arms). Primary endpoint: Percentage of participants who achieved a renal response at Week 52.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-003201-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003201-34.